Abstract | BACKGROUND: METHODS: Twenty four male C57BL/6 mice were divided into control and obese groups. The control group was fed a normal diet whereas the obese group was fed a high fat diet. After 16 weeks, 2×10(6) B16F10 melanoma cells were injected subcutaneously into all animals. Half of the control and the obese animals received 1 µM, 100 µL/kg NPY Y2 receptor antagonist ( BIIE 0246) intraperitoneally. After two weeks, the animals were sacrificed, and angiogenic factors and tumor weights and angiogenesis were analyzed. RESULTS:
Tumor weight in the obese mice was higher than in the control (p<0.05). Treatment with BIIE 0246 reduced tumor weight in the obese animals (p<0.05), without effect on control group (p>0.05). Administration of an NPY Y2 receptor antagonist decreased tumor angiogenesis (evaluated as capillary density/mm2) and serum VEGF concentration in the obese group without altering serum VEGF-R1 and NO concentrations. CONCLUSIONS:
|
Authors | Masoud Alasvand, Bahman Rashidi, S H Javanmard, Maziar Mohammad Akhavan, Majid Khazaei |
Journal | Global journal of health science
(Glob J Health Sci)
Vol. 7
Issue 7 Spec No
Pg. 69-78
(Mar 26 2015)
ISSN: 1916-9736 [Print] Canada |
PMID | 26153206
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Receptors, Neuropeptide Y
- Vascular Endothelial Growth Factor A
- neuropeptide Y2 receptor
- Nitric Oxide
- Vascular Endothelial Growth Factor Receptor-1
|
Topics |
- Animals
- Body Weight
- Disease Models, Animal
- Male
- Melanoma, Experimental
(drug therapy, epidemiology)
- Mice
- Mice, Inbred C57BL
- Neovascularization, Pathologic
(drug therapy)
- Nitric Oxide
(blood)
- Obesity
(epidemiology)
- Receptors, Neuropeptide Y
(antagonists & inhibitors)
- Skin Neoplasms
(drug therapy, epidemiology)
- Tumor Burden
- Vascular Endothelial Growth Factor A
(blood)
- Vascular Endothelial Growth Factor Receptor-1
(blood)
|